AstraZeneca

Health
India says Brazil rushed to send plane for vaccine
India says Brazil rushed to send plane for vaccine
Credit: Tony Winston/MS (Public Domain)

A spokesman for the Indian Foreign Ministry told the Hindustan Times that it was "too early" to send the batches of the vaccine, produced by the Serum Institute in partnership with Oxford University and pharmacist AstraZeneca.

On 5 January, Brazil's Foreign Ministry confirmed the purchase of Oxford vaccine doses produced in India, despite the Indian government's announcement that the vaccine's export was banned. The statement also mentioned plans to distribute the vaccines to Brazilian states within a few days of authorization from the National Health Surveillance Agency (Anvisa) and highlighted the successful acquisition of the doses with an example of the "excellent relations" between the two countries.

Health
AstraZeneca applies for approval of Covid-19 in European Union
AstraZeneca applies for approval of Covid-19 in European Union
Credit: Ashley Winkler for Pendect

The European Medicines Agency (EMA) has announced that AstraZeneca has applied for approval of their Covid-19 which has been developed by AstraZeneca and Oxford University.

According to the EMA "the assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline" and added that "an opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human medicines (CHMP), provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete and that any additional information required to complete the assessment is promptly submitted."

Regional News • Europe • United Kingdom
UK to roll out Oxford/AstraZeneca vaccine starting Monday

The UK is set to start administering the new Covid-19 vaccine from Oxford University and the AstraZeneca group on Monday, stating that the "NHS will be the first health service in the world to provide this life-saving vaccine."

The vaccine will initially be delivered in a small number of hospitals, but will be widely distributed to hundreds of vaccination centers later this week.

Regional News • Asia • India
India approves Oxford/AstraZeneca vaccine for emergency use

An expert panel of India's Central Drugs Standard Control Organisation (CDSCO) approved the Oxford/AstraZeneca coronavirus vaccine for emergency use on Friday, making it the third country to approve the vaccine. The CDSCO may also approve a locally developed vaccine by Bharat Biotech and the Indian Council of Medical Research (ICMR) soon.

Health
United Kingdom approves Oxford-AstraZeneca Covid-19 for use
United Kingdom approves Oxford-AstraZeneca Covid-19 for use
Credit: Ashles Winkler for Pendect

The Oxford-AstraZeneca vaccine has been approved for use in the UK, with the first doses due to be given on Monday amid rising coronavirus cases. This will cover the entire population when combined with the full order of the Pfizer-BioNTech jab, Health Secretary Matt Hancock said.

Regional News • Americas • Brazil
Brazil to start Covid-19 vaccine rollout in February, health care workers and high-risk groups go first
Brazil to start Covid-19 vaccine rollout in February, health care workers and high-risk groups go first
Credit: Illustration for Pendect by Ashley Winkler (Creative Commons Attribution ShareAlike 4.0)

Brazil's Ministry of Health has announced its national Covid-19 vaccination rollout plan on Wednesday. The country has negotiated a 300 million doses deal with "Fiocruz / AstraZeneca (100.4 million doses) and the COVAX Facility (42.9 million doses)" and will start vaccinating its people in February. Health and educational workers, the indigenous population, elderly people over 75 years old, those with pre-existing health conditions, security forces and transport officials will receive the vaccine first.

Health
AstraZeneca likely to do another study of Covid-19 vaccine after accidental lower dose shows higher efficacy
AstraZeneca likely to do another study of Covid-19 vaccine after accidental lower dose shows higher efficacy
Credit: unsplash/ Obi Onyeador

AstraZeneca and Oxford University on Wednesday acknowledged a manufacturing error that has raised questions about their Covid-19 vaccine after revealing earlier this week it was “highly effective” against the disease. AstraZeneca is likely to conduct an additional global trial to assess the efficacy of its Covid-19 vaccine, according to the company’s CEO.

The vaccine's rollout to the rest of the world likely won't be affected, according to AstraZeneca's CEO, since the studies that have been conducted, including safety data, are already in place from participants around the world outside of the U.S.

While vaccine candidates from Moderna and Pfizer have also shown robust efficacy in early Phase 3 data, hopes are riding high on the AstraZeneca version because it relies on a different technology, can be stored and transported at standard refrigerator temperatures rather than frozen, and costs just a fraction per dose compared to the other two leading vaccines in development.

Health
AstraZeneca's Covid-19 vaccine averages 70% efficacy
AstraZeneca's Covid-19 vaccine averages 70% efficacy
Credit: D Wells / via Wikimedia Commons (Creative Commons Attribution ShareAlike 4.0)

Pharmaceutical giant AstraZeneca announced Monday that its Covid-19 vaccine has shown an average efficacy of 70% in large-scale trials. When given as a half dose followed by a full dose a month later, it showed 90% efficacy and with two full doses given a month apart, it showed 62% efficacy.

"What we've always tried to do with a vaccine is fool the immune system into thinking that there's a dangerous infection there that it needs to respond to -- but doing it in a very safe way. So we get the immune response and we get the immune memory ... waiting and ready if the pathogen itself is then encountered," so Professor Andrew Pollard, the trial's lead investigator at Oxford.

Regional News • Europe • European Union
EU finalizes contract for Covid-19 vaccine
EU finalizes contract for Covid-19 vaccine
Credit: unsplash.com / Guillaume Périgois

The EU Commission has ended talks with the pharmaceutical companies Biontech and Pfizer on the supply of a corona vaccine. The vaccine developed by them prevents in more than 90 percent of cases a disease caused by the corona virus Covid-19, the pharmaceutical companies had announced.

According to the German Federal Minister of Health Jens Spahn, the EU has also already concluded agreements with the pharmaceutical companies Astra Zeneca and Sanofi, which are also working on corona vaccines.

Health
AstraZeneca Covid-19 vaccine trial volunteer that has been given placebo dies
João Pedro Feitosa
João Pedro Feitosa Credit: Facebook Reproduction

A volunteer in the clinical trial of the Covid-19 vaccine developed by AstraZeneca and Oxford University has died on October 15 in Brazil, the Brazilian health authority (Anvisa) announced.

The volunteer, João Pedro R. Feitosa, has died due to complications from Covid-19. Still, according to the Brazilian newspaper, O Globo Feitosa has been given a placebo and not the trial vaccine.

Oxford confirmed the clinical trial would not be paused, stating that after careful assessment "there have been no concerns about the safety of the clinical trial."

Health
AstraZeneca Covid-19 vaccine trial resumes after pausing over safety concerns
AstraZeneca Covid-19 vaccine trial resumes after pausing over safety concerns
Credit: AstraZeneca

Clinical trials for the AstraZeneca Covid-19 vaccine have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.

The company paused trials earlier this week after a possible adverse severe reaction in one participant.

In a statement, the company said it "will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic."

Health
AstraZeneca puts on hold Covid-19 vaccine trial after possible serious adverse reaction in participant
AstraZeneca Researcher
AstraZeneca Researcher Credit: AstraZeneca

AstraZeneca announced the Phase 3 trials of its Covid-19 vaccine had been put on hold due to a possible adverse reaction in a participant. The pharmaceutical manufacturer stated pausing tests were common during vaccine development and an independent committee is to review the safety data related to the adverse reaction.

"This is a routine action which has to happen whenever there is a potentially unexplained illness in one of the trials, while it is investigated, ensuring we maintain the integrity of the trials."

There are currently nine vaccine candidates in Phase 3 trials. AstraZeneca's is the first Phase 3 Covid-19 vaccine trial known to have been put on hold ,and it’s unclear how long the hold might last.

Business • Health Care
Nine biopharmaceutical companies sign safety pledge for Covid-19 vaccine
Nine biopharmaceutical companies sign safety pledge for Covid-19 vaccine
Credit: unsplash.com/CDC

Nine biopharmaceutical companies have signed a safety pledge, committing to "developing and testing potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles."

AstraZeneca, BioNTech, Moderna, Pfizer, Novavax, Sanofi, GlaxoSmithKline, Johnson & Johnson and Merck have signed the pledge just a week after the CDC's vaccine distribution plans surfaced, suggesting a vaccine would be available by as early as late October.

Regional News • Americas
Argentina, Mexico to produce AstraZeneca Covid-19 vaccine
Ginés González García and Alberto Fernández
Ginés González García and Alberto Fernández Credit: Argentina.gob.ar (Public Domain)

Argentinean President Alberto Fernández announced Wednesday that the private laboratory AstraZeneca would begin to produce in Argentina and Mexico a vaccine against the coronavirus that is developed in conjunction with the University of Oxford.

The president explained the goal is "to produce between 150 and 250 million vaccines for all of Latin America -except for Brazil- that will be available by the first half of 2021."

Fernández stated, "Latin American production will be in charge of Argentina and Mexico, and that will allow timely and sufficient access to potential vaccine for all countries in the region."

Regional News • Europe • United Kingdom
UK Government Secures 60m More Doses of COVID-19 vaccine
Glaxo Smith Kline Offices on the Great West Road at Brentford
Glaxo Smith Kline Offices on the Great West Road at Brentford Credit: Maxwell Hamilton / Wikimedia Commons (Creative Commons Attribution ShareAlike 3.0)

The UK government signed a deal with drug giants GSK and Sanofi for 60 million doses of an experimental COVID-19 vaccine. This is the country's fourth COVID-19 vaccination deal. The UK previously secured 100m doses from AstraZeneca and 90m doses from the alliance between Valneva, BioNtech and Pfizer.

Health
AstraZeneca to distribute 2 billion doses of Covid-19 vaccine at no profit
AstraZeneca Manufacturing
AstraZeneca Manufacturing Credit: AstraZeneca

AstraZeneca, which will produce the promising Covid-19 vaccine developed by the University of Oxford, announced Tuesday that it will distribute 2 billion doses at cost.

The announcement was made by Menelas Pangalos, executive vice president of the company, in a virtual meeting before an investigative subcommittee of the Energy and Commerce Committee of the US Congress.

Regional News • Americas • Brazil
Brazil to start production of experimental Covid-19 vaccine
Brazil to start production of experimental Covid-19 vaccine
Credit: Centers for Disease Control and Prevention (Creative Commons CC0 Waiver)

The Brazilian government has announced on Saturday that it will start producing an experimental Covid-19 vaccine locally. The government has signed an agreement worth $127 million with AstraZeneca who developed the experimental vaccine. According to the World Health Organization the vaccine is considered the world's leading candidate which has been developed by researchers at Oxford University in the United Kingdom. Human trials are still undergoing and final proof of the effect against Covid-19 is still pending.

Regional News • Americas • Brazil
Brazil is close to a deal to produce Oxford Covid-19 vaccine
Brazil is close to a deal to produce Oxford Covid-19 vaccine
Credit: Centers for Disease Control and Prevention (Creative Commons CC0 Waiver)

Brazilian interim Health Minister Eduardo Pazuello said Brazil is close to signing a contract to produce a trial vaccine developed by the Oxford University and supported by AstraZeneca.

The country started human clinical trials for the potential vaccine this weekend with 3,000 people in São Paulo and Rio de Janeiro, becoming the first country outside the United Kingdom to test the vaccine.

Oxford researchers expect to launch the vaccine by year-end.

Regional News • Europe
AstraZeneca agrees to supply Europe Union members with 400 million doses of Covid-19 vaccine
AstraZeneca Manufacturing
AstraZeneca Manufacturing Credit: AstraZeneca

Europe’s Inclusive Vaccines Alliance (IVA), a group formed by the Netherlands, Germany, France and Italy, concluded a contract with AstraZeneca to provide 400 million doses of a possible vaccine developed by the University of Oxford. If the trial results convince regulators the vaccine is safe and effective, deliveries are expected to start by the end of 2020.

The company reached similar agreements with the United Kingdom and with the United States.

Science • Medicine
University of Oxford Plans to Roll Out Covid-19 Vaccine by September if Trials Successfull
University of Oxford
University of Oxford Credit: unsplash.com/Tetiana SHYSHKINA

In his Sunday briefing, Business Secretary Alok Sharma said clinical trials for the Covid-19 vaccine by the University of Oxford were progressing well. The trial is currently in phase one and all participants have received their doses. Oxford has received over £47 million by the government so far and Sharma announced another £84 million in new funding.

Sharma added: "This means that if the vaccine is successful AstraZeneca (a British-Swedish multinational pharmaceutical and biopharmaceutical company) will work to make 30 million doses available by September for the UK as part of an agreement for over 100 million doses in total."